The strong EPS beat, positive adjusted EBITDA, and raised gross margin guidance signal improving operational leverage and a potential path to sustained profitability. Traders should watch for continued Greenbrook revenue growth and cash burn trajectory; the narrowed revenue guidance midpoint is unchanged, so the beat is largely a margin story. Monitor next quarter for further progress toward positive cash flow from operations and investing.
Price Chart
Executive Summary
Neuronetics reported Q2 2026 revenue of $41.6M (+9.1% YoY), beating the $40.2M consensus, and EPS of -$0.05, a 59.2% beat vs the -$0.12 estimate. The headline beat was driven by strong Greenbrook clinic revenue (+16.8% YoY to $26.9M) and a 460bps gross margin expansion to 51.1%, while NeuroStar system revenue declined 2.7% YoY. The company narrowed FY 2026 revenue guidance to $160M-$164M (from $160M-$166M) and raised gross margin guidance to 48%-50%, signaling improving operational leverage and a path toward breakeven, though cash burn remains a concern with $24.9M total cash at quarter-end.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $41.6M, +9.1% YoY, beating $40.2M consensus
- EPS -$0.05, a 59.2% beat vs consensus -$0.12
- Greenbrook clinic revenue $26.9M, +16.8% YoY
- Gross margin expanded 460bps to 51.1% from 46.6%
- Adjusted EBITDA turned positive at $0.3M vs -$5.6M loss YoY
- Net loss narrowed to $3.4M from $10.1M YoY
- FY 2026 revenue guidance narrowed to $160M-$164M (from $160M-$166M)
- FY 2026 gross margin guidance raised to 48%-50% (from 47%-49%)
- Operating expense guidance lowered to $95M-$100M (from $100M-$105M)
- Total cash $24.9M as of June 30, 2026, down from $34.1M at Dec 31, 2025
Financial Impact
Revenue beat of $1.4M (3.5%) and EPS beat of $0.07 (59.2%) vs consensus; gross margin expansion of 460bps; adjusted EBITDA swing of +$5.9M vs prior year
Risk Factors
- NeuroStar system revenue declined 2.7% YoY, indicating potential market share loss or demand weakness in capital equipment
- Cash burn continues: total cash declined $9.2M in H1 2026 to $24.9M
- FY 2026 revenue guidance midpoint unchanged at $162M, limiting upside surprise potential
- Net loss per share still negative at -$0.05; profitability not yet achieved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342616 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 11w ago | 8-K | $3.19 $3.21 | ▲ +0.63% | ▲ +0.38% | $2.23 (−30.15%) |
Aug 11, 2026 11w ago | Press Release | $3.19 $3.21 | ▲ +0.63% | ▲ +0.38% | $2.23 (−30.15%) |
Jun 23, 2026 17w ago | 8-K | $1.26 $1.27 | ▲ +0.79% | ▲ +0.65% | $2.23 (+76.83%) |
May 22, 2026 22w ago | 8-K | $1.20 $1.22 | ▲ +1.67% | ▲ +1.08% | $2.23 (+85.68%) |
May 5, 2026 25w ago | 8-K | $2.17 $1.91 | ▼ −11.98% | ▼ −13.37% | $2.23 (+2.68%) |
May 5, 2026 25w ago | Press Release | $2.17 $1.91 | ▼ −11.98% | ▼ −13.37% | $2.23 (+2.68%) |
Apr 21, 2026 27w ago | Press Release | $1.50 $1.59 | ▲ +6.00% | ▲ +4.98% | $2.23 (+48.54%) |
Apr 13, 2026 28w ago | EFFECT | $1.39 $1.43 | ▼ −2.88% | ▼ −1.67% | $2.23 (−60.29%) |
Mar 19, 2026 31w ago | Insider Cluster | $1.52 $1.45 | ▼ −4.29% | ▼ −2.55% | $2.23 (+47.07%) |
Mar 19, 2026 31w ago | Insider Cluster | $1.52 $1.45 | ▼ −4.29% | ▼ −2.55% | $2.23 (+47.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers